Update on antiangiogenic therapy in colorectal cancer

Aflibercept and regorafenib

Potjana Jitawatanarat, Wen Wee Ma

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Angiogenesis plays an important role in colorectal carcinogenesis and approaches targeting the vascular growth factor receptor (VEGF) signaling such as bevacizumab yielded significant survival improvement for metastatic colorectal cancer patients. Recent evidence demonstrated the benefit of continuing angiogenic suppression after first-progression following bevacizumab-containing cytotoxic regimen though no benefit was observed with the use of bevacizumab in adjuvant setting. Aflibercept, a soluble fusion protein with high affinity for VEGF-A, -B and PlGF, administered in combination with irinotecan-containing regimen improved the survival of metastatic colorectal cancer patients in second-line setting (VELOUR trial). Regorafenib, a small molecule multikinase inhibitor against various pro-angiogenic and -proliferation targets, improved the survival of metastatic colorectal cancer patients who had progressed on all standard therapy. These developments had renewed enthusiasm in the field and the role of aflibercept and regorafenib in other treatment settings will continue to be defined by on-going and future clinical trials. As other anti-angiogenic approaches are being tested clinically, other novel non-angiogenic targets deserve to be evaluated in our effort to improve the outcome of colorectal cancer patients.

Original languageEnglish (US)
Pages (from-to)231-238
Number of pages8
JournalJournal of Gastrointestinal Oncology
Volume4
Issue number2
DOIs
StatePublished - Jan 1 2013
Externally publishedYes

Fingerprint

Colorectal Neoplasms
irinotecan
Vascular Endothelial Growth Factor A
Survival
Vascular Endothelial Growth Factor B
Growth Factor Receptors
Therapeutics
Carcinogenesis
Clinical Trials
aflibercept
regorafenib
Bevacizumab
Proteins

Keywords

  • Aflibercept
  • Antiangiogenic therapy
  • Colorectal cancer
  • Regorafenib
  • Vascular growth factor receptor (VEGF)

ASJC Scopus subject areas

  • Oncology
  • Gastroenterology

Cite this

Update on antiangiogenic therapy in colorectal cancer : Aflibercept and regorafenib. / Jitawatanarat, Potjana; Ma, Wen Wee.

In: Journal of Gastrointestinal Oncology, Vol. 4, No. 2, 01.01.2013, p. 231-238.

Research output: Contribution to journalArticle

@article{40cabab88da0412797d30ba2fb03ff25,
title = "Update on antiangiogenic therapy in colorectal cancer: Aflibercept and regorafenib",
abstract = "Angiogenesis plays an important role in colorectal carcinogenesis and approaches targeting the vascular growth factor receptor (VEGF) signaling such as bevacizumab yielded significant survival improvement for metastatic colorectal cancer patients. Recent evidence demonstrated the benefit of continuing angiogenic suppression after first-progression following bevacizumab-containing cytotoxic regimen though no benefit was observed with the use of bevacizumab in adjuvant setting. Aflibercept, a soluble fusion protein with high affinity for VEGF-A, -B and PlGF, administered in combination with irinotecan-containing regimen improved the survival of metastatic colorectal cancer patients in second-line setting (VELOUR trial). Regorafenib, a small molecule multikinase inhibitor against various pro-angiogenic and -proliferation targets, improved the survival of metastatic colorectal cancer patients who had progressed on all standard therapy. These developments had renewed enthusiasm in the field and the role of aflibercept and regorafenib in other treatment settings will continue to be defined by on-going and future clinical trials. As other anti-angiogenic approaches are being tested clinically, other novel non-angiogenic targets deserve to be evaluated in our effort to improve the outcome of colorectal cancer patients.",
keywords = "Aflibercept, Antiangiogenic therapy, Colorectal cancer, Regorafenib, Vascular growth factor receptor (VEGF)",
author = "Potjana Jitawatanarat and Ma, {Wen Wee}",
year = "2013",
month = "1",
day = "1",
doi = "10.3978/j.issn.2078-6891.2013.008",
language = "English (US)",
volume = "4",
pages = "231--238",
journal = "Journal of Gastrointestinal Oncology",
issn = "2078-6891",
publisher = "Pioneer Bioscience Publishing Company (PBPC)",
number = "2",

}

TY - JOUR

T1 - Update on antiangiogenic therapy in colorectal cancer

T2 - Aflibercept and regorafenib

AU - Jitawatanarat, Potjana

AU - Ma, Wen Wee

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Angiogenesis plays an important role in colorectal carcinogenesis and approaches targeting the vascular growth factor receptor (VEGF) signaling such as bevacizumab yielded significant survival improvement for metastatic colorectal cancer patients. Recent evidence demonstrated the benefit of continuing angiogenic suppression after first-progression following bevacizumab-containing cytotoxic regimen though no benefit was observed with the use of bevacizumab in adjuvant setting. Aflibercept, a soluble fusion protein with high affinity for VEGF-A, -B and PlGF, administered in combination with irinotecan-containing regimen improved the survival of metastatic colorectal cancer patients in second-line setting (VELOUR trial). Regorafenib, a small molecule multikinase inhibitor against various pro-angiogenic and -proliferation targets, improved the survival of metastatic colorectal cancer patients who had progressed on all standard therapy. These developments had renewed enthusiasm in the field and the role of aflibercept and regorafenib in other treatment settings will continue to be defined by on-going and future clinical trials. As other anti-angiogenic approaches are being tested clinically, other novel non-angiogenic targets deserve to be evaluated in our effort to improve the outcome of colorectal cancer patients.

AB - Angiogenesis plays an important role in colorectal carcinogenesis and approaches targeting the vascular growth factor receptor (VEGF) signaling such as bevacizumab yielded significant survival improvement for metastatic colorectal cancer patients. Recent evidence demonstrated the benefit of continuing angiogenic suppression after first-progression following bevacizumab-containing cytotoxic regimen though no benefit was observed with the use of bevacizumab in adjuvant setting. Aflibercept, a soluble fusion protein with high affinity for VEGF-A, -B and PlGF, administered in combination with irinotecan-containing regimen improved the survival of metastatic colorectal cancer patients in second-line setting (VELOUR trial). Regorafenib, a small molecule multikinase inhibitor against various pro-angiogenic and -proliferation targets, improved the survival of metastatic colorectal cancer patients who had progressed on all standard therapy. These developments had renewed enthusiasm in the field and the role of aflibercept and regorafenib in other treatment settings will continue to be defined by on-going and future clinical trials. As other anti-angiogenic approaches are being tested clinically, other novel non-angiogenic targets deserve to be evaluated in our effort to improve the outcome of colorectal cancer patients.

KW - Aflibercept

KW - Antiangiogenic therapy

KW - Colorectal cancer

KW - Regorafenib

KW - Vascular growth factor receptor (VEGF)

UR - http://www.scopus.com/inward/record.url?scp=84995743346&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995743346&partnerID=8YFLogxK

U2 - 10.3978/j.issn.2078-6891.2013.008

DO - 10.3978/j.issn.2078-6891.2013.008

M3 - Article

VL - 4

SP - 231

EP - 238

JO - Journal of Gastrointestinal Oncology

JF - Journal of Gastrointestinal Oncology

SN - 2078-6891

IS - 2

ER -